摘要
目的:探讨重组人脑利钠肽(recombinant human brain natriuretic peptide,rh BNP)对急性心力衰竭患者血清25羟维生素D[25-(OH)D3]水平的影响。方法:选取惠州市第三人民医院收治的急性心力衰竭患者120例作为研究对象,采用随机数字表法分为观察组和对照组各60例,对照组患者采用卧床休息、药物与对症支持治疗,观察组患者在对照组治疗的基础上采用rh BNP治疗。结果:观察组患者显效率为61.67%(37/60)、总有效率为90.00%(54/60),均明显高于对照组的36.67%(22/60)、63.33%(38/60),2组的差异有统计学意义(P<0.05)。治疗前,2组患者血清25-(OH)D3水平、左心室射血分数(left ventricular ejection fraction,LVEF)、左室后壁厚度(left ventricular posterior wall thickness,LVPWD),左室舒张末期内径(left ventricular end diastolic diameter,LVEDD)比较,差异无统计学意义(P>0.05)。治疗后,观察组和对照组患者的血清25-(OH)D3水平为(22.36±5.41)、(18.01±4.64)ng/ml,均明显高于治疗前的(15.24±4.21)、(15.19±3.98)ng/ml,且观察组患者的血清25-(OH)D3水平明显高于对照组,差异有统计学意义(P<0.05);2组患者LVEF明显高于治疗前,LVPWD、LVEDD明显低于治疗前,且观察组患者的LVEF明显高于对照组,LVPWD、LVEDD明显低于对照组,差异有统计学意义(P<0.05)。结论:rh BNP治疗急性心力衰竭患者疗效显著,显著改善血清25-(OH)D3与各心功能指标,且无明显不良反应,值得临床推广。
OBJECTIVE： To investigate the effects of recombinant human brain natriuretic peptide（ rh BNP） on serum 25-（ OH） D3 level of patients with acute heart failure. METHODS： 120 cases with acute heart failure admitted into Third People＇s Hospital of Huizhou were selected to be divided into observation group and control group via the random number table,with 60 cases in each group. The control group were treated with bed rest combined with medicine and symptomatic support treatment,while the observation group additionally received rh BNP based on the control group. RESULTS： The significant efficiency and total efficiency of observation group were significantly higher than than of control group[61. 67%（ 37 /60） VS 36. 67%（ 22 /60）,90. 00%（ 54 /60） VS 63. 33%（ 38 /60） ],the difference was statistically significant（ P〈0. 05）. Before treatment,the serum 25-（ OH） D3 levels,left ventricular ejection fraction（ LVEF）,left ventricular posterior wall thickness（ LVPWD） and left ventricular end diastolicdiameter（ LVEDD） between two groups was not statistically significant（ P〈0. 05）. After treatment,compared with before treatment,the serum 25-（ OH） D3 levels in observation group and control group had been significantly increased[（ 22. 36 ± 5. 41） ng /ml and（ 18. 01 ± 4. 64） ng /ml VS（ 15. 24 ± 4. 21） ng /ml and（ 15. 19 ± 3. 98） ng /ml],and the serum 25-（ OH） D3 levels of observation group were significantly higher than that of control group,with statistically significant difference（ P〈0. 05）. LVEF of two groups were significantly higher than before treatment,and LVPWD,LVEDD were significantly lower than after treatment; meanwhile,LVEF of observation group were significantly higher than that of control group,but LVPWD,LVEDD were significantly lower,with statistically significant difference（ P〈0. 05）. CONCLUSIONS： Recombinant human brain natriuretic peptide in treatment of patients with acute heart failure has significant efficacy,which can significantly improve the serum 25-（ OH） D3 and cardiac function indicators with no obvious adverse reactions. It is worthy of clinical application.
出处
《中国医院用药评价与分析》
2015年第12期1577-1579,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
